Jamieson Wellness (TSX:JWEL) is a Toronto-based manufacturer, distributor, and marketer of natural health products. The global dietary supplements market is expected to continue to post solid growth well into this new decade. Grand View Research forecasts that it will reach $194 billion u.s. by 2025, which would represent a CAGR of 7.8% during the forecast period from 2018.
Shares of Jamieson have climbed 26% year-over-year as of close on January 10. The stock is well-positioned to gain off these global trends over the course of the 2020s. Its expansion into Asia is especially exciting.
The company is expected to release its fourth quarter and full-year results for 2019 in late February. In the third quarter of fiscal 2019, Jamieson reported consolidated revenue of $88.6 million which was up 11.2% from the prior year. Adjusted EBITDA rose 8.6% to $19.4 million and adjusted net income increased 7.2% to $9.5 million.
Jamieson began shipping into domestic channels in China in the third quarter. The company reported a 23.9% increase in international sales which was led by strong growth in China. Its push into Asia is still in its early stages, so there is good reason to be excited about its prospects there going forward.
The stock last had a price-to-earnings ratio of 36 and a price-to-book value of 4.1. Jamieson is trading at a premium right now, so growth investors may not want to jump on before a more attractive entry point presents itself.
